Statistics for Aligos Therapeutics (id:8426 ALGS)

Valuation metrics

Market cap

69.82M

Enterprise value

4.03M

Trailing P/E (ttm)

-0.59

Forward P/E

-1.63

PEG ratio

-1.63

Price/Sales (ttm)

11.64

Price/Book (mrq)

1.29

Enterprise Value/Revenue

0.67

Enterprise Value/EBITDA

-0.04

Overview

Shares outstanding

3.46M

Float

419.89K

Shares short

121.30K

% Held by insiders

0.18%

% Held by institutions

0.55%

Average volume (10 days)

709.58K

Average volume (90 days)

Price summary

52-Week low

6.76

52-Week high

30.00

52-Week change

11.68%

Beta

2.12

50-Day moving average

10.11

200-Day moving average

15.29

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

Ex-dividend date

Last split factor

2:1

Last split date

August 19th, 2024

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

0.00%

Operating margin

-1,586.37%

Operational effectiveness

Return on assets

-67.32%

Return on equity

-146.69%

Income statement

Revenue (ttm)

1.00

Revenue per share (ttm)

1.00

Quarterly revenue growth (yoy)

Gross profit (ttm)

0.00

EBITDA

-92,684,000.00

Net income to common (ttm)

-76,953,000.00

Diluted EPS (ttm)

-7.25

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

74.92M

Total cash per share (mrq)

20.88

Total debt (mrq)

9.13M

Total Debt/Equity (mrq)

18.23

Current ratio (mrq)

380.90%

Book value per share (mrq)

15.07

Cash flow

Cash flow statement

-84,998,000.00

Levered free cash flow (LFCF)

-49,061,000.00